The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy
详细信息 查看全文
- 作者：Mariusz Klopotowski (1)
Lidia Chojnowska (1)
Lukasz A. Malek (1)
Renata Maczynska (1)
Krzysztof Kukula (1)
Marcin Demkow (1)
Adam Witkowski (1)
Maciej Dabrowski (1)
Maciej Karcz (1)
Rafal Baranowski (2)
Beata Kusmierczyk-Droszcz (3)
Mariusz Kruk (1)
Jacek Jamiolkowski (4)
Mariusz Kusmierczyk (5)
Lukasz Szumowski (6)
Witold Ruzyllo (1) - 关键词：Ventricular tachycardia ; Hypertrophic cardiomyopathy ; Alcohol septal ablation
- 刊名：Clinical Research in Cardiology
- 出版年：2010
- 出版时间：May 2010
- 年：2010
- 卷：99
- 期：5
- 页码：285-292
- 全文大小：283KB
- 参考文献：1. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS (2008) Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51:1369-374 CrossRef
2. Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, Haberl R, Steinbeck G (2001) Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:846-53 CrossRef
3. Bello D, Fieno DS, Kim RJ, Pereles FS, Passman R, Song G, Kadish AH, Goldberger JJ (2005) Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 45:1104-108 CrossRef
4. Boltwood CM Jr, Chien W, Ports T (2004) Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med 351:1914-915 CrossRef
5. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ (1998) Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 79:331-36
6. Chojnowska L, Ruzyllo W, Witkowski A, Demkow M, Kusmierczyk-Droszcz B, Kepka C, Konka M, Malecka L, Karcz M, Stepinska J (2003) Early and long-term results of non-surgical septal reduction in patients with hypertrophic cardiomyopathy. Kardiol Pol 59:269-82
7. Cuoco FA, Spencer WH III, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, Leman RB, Wharton JM, Gold MR (2008) Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol 52:1718-723 CrossRef
8. Elliott PM, Gimeno JR, Tome MT, Shan J, Ward D, Thaman R, Mogensen J, McKenna WJ (2006) Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 27:1933-941 CrossRef
9. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H (2007) One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol 96:864-73 CrossRef
10. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn HJ (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20:1342-354 CrossRef
11. Kuhn H (1999) Septal ablation in HOCM: is there an arrhythmogenic potential? 11th World Symposium on cardiac pacing and electrophysiology, Berlin 1999
12. Kuhn H, Gietzen FH, Leuner C, Sch?fers M, Schober O, Strunk-Müller C, Obergassel L, Freick M, Gockel B, Lieder F, Raute-Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol, 89 (Suppl 4) : IV 41-4
13. Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, Bartelsmeier M, Stellbrink C (2008) Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10?year experience. Clin Res Cardiol 97:234-43 CrossRef
14. Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, Tsang S, Davis RB (2006) Impact of unrecognized myocardial scar detected by cardiac resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 113:2733-743 CrossRef
15. Lawrenz T, Obergassel L, Lieder F, Leuner C, Strunk-Mueller C, Meyer Zu Vilsendorf D, Beer G, Kuhn H (2005) Transcoronary ablation of septal hypertrophy does not alert ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 28:295-00 CrossRef
16. Malek LA, Chojnowska L, Klopotowski M, Maczynska R, Demkow M, Witkowski A, Kusmierczyk B, Piotrowicz E, Konka M, Dabrowski M, Ruzyllo W (2008) Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation. Eur J Heart Fail 10:1123-126 CrossRef
17. Maron BJ (2007) Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 116:196-06 CrossRef
18. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298:405-12 CrossRef
19. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114:2232-239 CrossRef
20. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ (2003) Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 42:873-79 CrossRef
21. Obergassel L, Lawrenz T, Gietzen FH, Lieder F, Leuner C, Kuhn H, Stellbrink C (2006) Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation. Clin Res Cardiol 95:254-60 CrossRef
22. Raute-Kreinsen U (2003) Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy. Pathol Res Pract 1999:121-27 CrossRef
23. Ruzyllo W, Chojnowska L, Demkow M, Witkowski A, Kusmierczyk-Droszcz B, Piotrowski W, Rausinska L, Karcz M, Malecka L, Rydlewska-Sadowska W (2000) Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 21:770-77 CrossRef
24. Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L (2007) Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 96:856-63 CrossRef
25. Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211-14 CrossRef
26. Soliman OI, Geleijnse ML, Michels M, Dijkmans PA, Nemes A, van Dalen BM, Vletter WB, Serruys PW, Ten Cate FJ (2008) Effect of successful alcohol septal ablation on microvascular function in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 101:1321-327 CrossRef
27. Streit S, Walpoth N, Windecker S, Meier B, Hess O (2007) Is alcohol ablation of the septum associated with recurrent tachyarrhythmias? Swiss Med Wkly 137:660-68
28. van Dockum WG, Kuijer JP, Gotte MJ, Ten Cate FJ, Ten Berg JM, Beek AM, Twisk JW, Marcus JT, Visser CA, van Rossum AC (2006) Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis. Eur Heart J 27:2833-839 CrossRef
29. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CS, Schaff HV, Maron BJ (2007) Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 49:350-57 CrossRef
30. Veselka J, Honek T (2003) Early remodeling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol 88:27-2 CrossRef - 作者单位：Mariusz Klopotowski (1)
Lidia Chojnowska (1)
Lukasz A. Malek (1)
Renata Maczynska (1)
Krzysztof Kukula (1)
Marcin Demkow (1)
Adam Witkowski (1)
Maciej Dabrowski (1)
Maciej Karcz (1)
Rafal Baranowski (2)
Beata Kusmierczyk-Droszcz (3)
Mariusz Kruk (1)
Jacek Jamiolkowski (4)
Mariusz Kusmierczyk (5)
Lukasz Szumowski (6)
Witold Ruzyllo (1)
1. 1st Department of Coronary Artery Disease and 2nd Catheterization Laboratory, Institute of Cardiology, Alpejska 42, 04-628, Warsaw, Poland
2. Department of Cardiac Rehabilitation and Noninvasive Electrocardiology, Institute of Cardiology, 04-628, Warsaw, Poland
3. Department of Congenital Heart Disease and Echocardiographic Laboratory, Institute of Cardiology, 04-628, Warsaw, Poland
4. Department of Public Health, Medical University of Bialystok, Bialystok, Poland
5. 2nd Department of Cardiac Surgery and Heart Transplantation, Institute of Cardiology, 04-628, Warsaw, Poland
6. Department of Cardiac Electrophysiology, Institute of Cardiology, 04-628, Warsaw, Poland
文摘
Background Percutaneous alcohol septal ablation (ASA) becomes an alternative option of treatment for symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). The procedure relieves left ventricular outflow tract obstruction, but produces a myocardial scar in patients who already have a substrate for life-threatening ventricular arrhythmia. Objectives To examine the effect of ASA on the occurrence of non-sustained ventricular tachycardia (nsVT) on 24?h ambulatory Holter monitoring in HOCM patients. Methods Sixty-one consecutive patients (34 males, mean age 48 years), who underwent ASA between 1997 and 2003 were analyzed. Holter recordings were performed in each patient before and after ablation. Results Follow-up ranged from 60 to 125 months (median 116 months). The mean number of Holter recordings per patient was 2.7 (range 1-1) before and 8.3 (range 2-3) after ASA (p?<?0.001). Non-sustained ventricular tachycardia occurred in 14 patients before and 27 patients after ASA (23 vs. 44%, p?=?0.01). The percentage of Holter recordings with nsVT before and after ablation was similar (14.5 vs. 15.7%, p?=?0.56, respectively). No difference was observed between the number of nsVT per Holter recording before and after ablation (0.21 vs. 0.24%, p?=?0.65, respectively). The percentage of patients with nsVT after ASA was comparable to the proportion of patients with nsVT in a control group consisting of 705 patients with hypertrophic cardiomyopathy under follow-up at our institution (44.3 vs. 43.2%, p?=?0.91). There was no significant difference in percentage of Holter recordings with nsVT with respect to sex, amount of alcohol used during ASA, peak creatine phosphokinase level, and gradient reduction at rest. Conclusion Alcohol septal ablation affected neither the percentage of Holter recordings with nsVT nor the number of nsVT episodes per Holter recording among HOCM patients.